Transdermal scopolamine for reduction of drooling in developmentally delayed children.
Ten developmentally delayed children with excessive drooling were randomized in a double-blind, placebo-controlled study to assess the efficacy and safety of transdermal scopolamine. Over half of the patients had a statistically significant reduction in drooling, and one-third had cessation of drooling, while wearing the scopolamine patch. This short-term study supports earlier reports of the safety and efficacy of transdermal scopolamine for reducing excessive drooling in developmentally disabled children.
Lewis
D W
DW
Department of Pediatrics and Neurology, US Naval Hospital, Portsmouth, VA 23708.
Fontana
C
C
Mehallick
L K
LK
Everett
Y
Y
D000279:Administration, Cutaneous; D000293:Adolescent; D002648:Child; D002658:Developmental Disabilities / Q000150:complications*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010919:Placebos; D012601:Scopolamine / Q000627:therapeutic use*; D012798:Sialorrhea / Q000188:drug therapy* / Q000209:etiology
D010919:Placebos; D012601:Scopolamine